HIPRA has launched the first in-ovo vaccine against coccidiosis into the European market.
Evanovo is a live attenuated parasitic vaccine against coccidiosis developed for in-ovo administration to broilers and has been brought to market in Europe.
It is available in both the UK, NI and Europe, according to Spanish pharmaceutical outfit Hipra.
One of the advantages of in-ovo vaccination is that uniform administration of each bird is ensured at the same time, Hipra added.
Accfording to the European Medicines Agency, the onset of immunity is 21 days of age, and the duration of immunity is 63 days of age.
It targets Eimeria acervulina, Eimeria maxima and Eimeria praecox, and the reduction of clinical signs, intestinal lesions and oocysts output associated with coccidiosis caused by Eimeria tenella.
The new vaccine can be given in the same injection as other inoculations such as Hipra’s immune-complex vaccine against Gumboro, Gumbohatch, for example.
In addition to the launch of Evanovo in late October, Hipra announced a number of supply chain support services.
“An example is the Global Hatchery Health Programme (GHHP) which focuses on helping the customer to maximize the health potential of the chick from the hatchery onwards by means of optimization of the vaccination processes,” a statement from the firm said.
“With this initiative, HIPRA once again positions itself as an expert in avian coccidiosis and consolidates its position as the reference in prevention for poultry health.”